---
title: "Sutro Biopharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.52 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286463635.md"
datetime: "2026-05-14T20:29:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286463635.md)
  - [en](https://longbridge.com/en/news/286463635.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286463635.md)
---

# Sutro Biopharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.52 M

Revenue: As of FY2026 Q1, the actual value is USD 14.52 M, beating the estimate of USD 7.411 M.

EPS: As of FY2026 Q1, the actual value is USD -2.94.

EBIT: As of FY2026 Q1, the actual value is USD -21.82 M.

The provided reference, a Form 8-K filing by Sutro Biopharma, Inc. dated May 14, 2026, states that the company issued a press release announcing its financial results for the quarter ended March 31, 2026. However, the Form 8-K itself does not contain the actual financial results, operational metrics, or any forward-looking outlook or guidance.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)

## Related News & Research

- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Sutro Biopharma Q1 revenue beats analyst expectations](https://longbridge.com/en/news/286462966.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)